PhD Supervisor, Chief Physician, Deputy Director of the Hematology Department at the First Affiliated Hospital of the University of Science and Technology of China (USTC), Head of the Southern Hematology Division, Young Leading Talent in Anhui Province's Health System.
Education and Work Experience
- 1991-1996: Bachelor’s degree in Clinical Medicine, Bengbu Medical College
- 1999-2002: Master’s degree in Immunology, Anhui Medical University
- 2002-2005: PhD in Hematology, Huazhong University of Science and Technology
- 2005-Present: Attending Physician, Associate Chief Physician, Chief Physician at the First Affiliated Hospital of USTC
- 2012: Visiting Scholar, Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation
- 2013: Visiting Scholar, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
Academic Achievements and Impact
With 20 years dedicated to clinical practice, research, and teaching in hematology, supervised 23 PhD and Master's students. Received the 15th Anhui Youth Science and Technology Award and three Second Prizes for Scientific and Technological Progress in Anhui Province (one as the primary contributor).
Published over 50 papers as first or corresponding author, including 16 in SCI journals.
Ongoing Projects (Principal Investigator Only)
Project Name, Source, Funding Indicator Number | Total Funding (10,000 CNY) | Start-End Date
- Clinical Application of Dual-Target CAR-T Cell Therapy for Relapsed/Refractory B-Cell Hematological Malignancies, Anhui Provincial Major Science and Technology Project | 100 | 2019-01 to 2021-06
Main Research Directions (Enrollment Specialties) and Content
Clinical Medicine
1. Hematology
- Research on diagnosis, treatment, and immune mechanisms of hematological tumors
- Development and clinical translation of immunotherapy for hematological tumors (e.g., CAR-T cells)
Representative Papers (Last Five Years)
1. Xu Q, Xu H, Xue L, et al. CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation. Chinese Medical Journal, 2021, Publish Ahead of Print. DOI: 10.1097/CM9.0000000000001491.
2. He Caixia, Xue Lei, Qiang Ping, et al. Efficacy and safety of CD19 CAR-T cell therapy in 14 cases of relapsed/refractory Ph+ acute B lymphoblastic leukemia. Chinese Journal of Hematology. 2020, 41(6): 490-494.
3. Xue Lei, Hu Yan, Wang Jian, et al. T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. Cancer Management and Research. 2019:11 6467–6476.
4. Li S#, Xue L#, Wang M, et al. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. OncoTargets and Therapy, 2019:12 5627–5638.
5. Wang X*, Ye X, Ji J, et al. MicroRNA 155 targets myosin light chain kinase to inhibit the migration of human bone marrow derived mesenchymal stem cells. Int J Mol Med. 2018, 42: 1585-1592.
6. Wang X*, Zhu Y, Xu B, Liu X. Identification of TLR2 and TLR4-induced microRNAs in Human Mesenchymal Stem Cells and their possible roles in regulating TLR signals. Molecular Medicine Reports. 2016; 13: 4969-4980.
Contact Information
E-mail: wangxingbing@ustc.edu.cn
Phone: 0551-62284476